NRX Pharmaceuticals, Inc. short interest in 2023
In 2023, NRX Pharmaceuticals, Inc.'s disclosed short interest ran from 1.93% of shares outstanding on 13 Jan 2023 to 3.20% on 29 Dec 2023, a change of +1.27 percentage points. The year's high was 3.20% on 29 Dec 2023 and its low 0.98% on 15 Aug 2023, averaging 1.90% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.56 days on 28 Apr 2023. Full history: NRX Pharmaceuticals, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.93% (13 Jan 2023)
- End of year
- 3.20% (29 Dec 2023)
- Change
- +1.27 pp
- High
- 3.20% (29 Dec 2023)
- Low
- 0.98% (15 Aug 2023)
- Average
- 1.90%
- Highest days to cover
- 20.56 (28 Apr 2023)
- SEC filings marked
- 6
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.93% | 3.49 | |
| 31 Jan 2023 | 1.75% | 4.25 | |
| 15 Feb 2023 | 1.69% | 7.59 | |
| 28 Feb 2023 | 1.84% | 12.46 | |
| 15 Mar 2023 | 2.09% | 6.85 | |
| 31 Mar 2023 | 2.24% | 8.47 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 2.22% | 11.43 | |
| 28 Apr 2023 | 2.16% | 20.56 | |
| 15 May 2023 | 1.92% | 10.17 | 10-Q filed |
| 31 May 2023 | 1.80% | 10.75 | |
| 15 Jun 2023 | 1.67% | 1.15 | |
| 30 Jun 2023 | 1.25% | 3.51 | |
| 14 Jul 2023 | 1.71% | 2.69 | |
| 31 Jul 2023 | 1.50% | 3.32 | |
| 15 Aug 2023 | 0.98% | 1.61 | 10-Q filed |
| 31 Aug 2023 | 1.76% | 1.00 | |
| 15 Sep 2023 | 1.79% | 1.00 | |
| 29 Sep 2023 | 2.62% | 3.18 | |
| 13 Oct 2023 | 2.32% | 2.79 | |
| 31 Oct 2023 | 1.92% | 4.12 | |
| 15 Nov 2023 | 1.83% | 4.28 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 1.75% | 5.29 | |
| 15 Dec 2023 | 1.59% | 5.69 | |
| 29 Dec 2023 | 3.20% | 1.00 |
See also: NRX Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.